Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07527741 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess Treatment Patterns and Treatment Adherence in Early HER2-positive Breast Cancer Participants After Treatment Decentralization

Study acronym: Close2HER
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later May 31, 2028 → Oct 31, 2028
See other at-risk trials from Roche/Genentech

Record History

  1. Primary and study completion pushed from May 31, 2028 to Oct 31, 2028
  2. Eligibility criteria expanded, about 6 words Secondary endpoints: details revised at 9 of 12 entries · Site details revised at 3 of 10 sites Show 2 more changesShow less
    • Secondary endpoints: details revised at 9 of 12 entries
    • Site details revised at 3 of 10 sites
  3. 3 versions Re-verified since Jul 4, 2026, no change to tracked fieldsv4-v6
  4. Study Status, Contacts/Locations, Referencesv3
  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main purpose of this study is to evaluate the impact of a decentralized treatment model on treatment adherence in participants with early-stage human epidermal growth factor receptor 2- positive (HER2+) breast cancer (BC). This study has 2 groups: Group 1: Consistent Travel Burden (Cohorts A, C, and D), will include participants whose adjuvant therapy location does not increase their travel requirements, and Group 2: Increased Travel Burden (Cohort B), will include participants who must travel from a secondary center to a tertiary center to receive their adjuvant therapy.
Trial Details
NCT Number NCT07527741
Lead Sponsor Hoffmann-La Roche
Conditions Early-stage HER2+ Breast Cancer
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov